Background: Advances in neonatal care have enabled the survival of extremely preterm infants. Some of them have growth failure and remain short at later ages. As a consequence, children born prematurely may be candidates for growth hormone (GH) treatment. Aims: The goal of this study was to obtain information about children on GH therapy enrolled in the Pfizer International Growth Database (KIGS) who were born prematurely. Patients: The KIGS database was queried for data on prepubertal short children (height <–2 standard deviation score; SDS) born with gestational age below 37 weeks. Birth weight had to be available. Results: In total, 3,215 patients were selected and classified according to gestational age and birth weight as preterm (<37 weeks’ gestation), very preterm (VP; <33 weeks’ gestation), appropriate for gestational age (AGA; birth weight between –2 and +2 SDS) or small for gestational age (SGA; birth weight <–2 SDS). Of these, 1,928 children were preterm AGA, 629 very preterm AGA, 519 preterm SGA, and 139 very preterm SGA. Conclusions: KIGS is a cumulative database and provides a unique opportunity to evaluate the growth response to GH therapy of premature children born with differences in gestational ages, size at birth, rate of postnatal growth, and GH secretion status.

Pilling EL, Elder CJ, Gibson AT: Growth patterns in the growth-retarded premature infant. Best Pract Res Clin Endocrinol Metab 2008;22:447–462.
Farooqi A, Hägglöf B, Sedin G, Gothefors L, Serenius F: Growth in 10- to 12-year-old children born at 23 to 25 week’s gestation in the 1990s: a Swedish National Prospective Follow-Up Study. Pediatrics 2006;118:e1452–e1456.
Knops NB, Sneeuw KC, Brand R, Hille ET, den Ouden AL, Wit JM, Verloove-Vanhorick SP: Catch-up growth up to ten years of age in children born very preterm or with very low birth weight. BMC Pediatr 2005;5:26–34.
Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P: An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977–1981). Acta Paediatr Scand 1991;80:756–762.
Prader A, Largo RH, Molinari L, Issler C: Physical growth of Swiss children from birth to 20 years of age; first Zurich longitudinal study of growth and development. Helv Paediatr Acta 1989;52(suppl):1–125.
Saenger P, Czernichow P, Hughes I, Reiter EO: Small for gestational age: short stature and beyond. Endocr Rev 2007;28:219–251.
Huysman MW, Hop WC, Cromme-Dijkhuis AH, Sauer PJ, Hokken-Koelega AC: A randomized, placebo-controlled GH trial in very preterm infants who were at risk for bronchopulmonary dysplasia and were treated with dexamethasone. Pediatr Res 2005;58:705–712.
de Kort SW, Willemsen RH, van der Kaay DC, Duivenvoorden HJ, Hokken-Koelega AC: Does preterm birth influence the response to growth hormone treatment in short, small for gestational age children? Clin Endocrinol 2009;70:582–587.
You do not currently have access to this content.